News

Open access drug development tools feature in new IMI Call for proposals

Published on: 29/01/2019

Open access drug development tools feature in new IMI Call for proposals

New open access tools for drug development, obesity, and the environmental impacts of medicines are the focus of a new IMI2 Call for proposals launched today. The total budget of the Call is over EUR 80 million. Half of this comes from the European Commission’s Horizon 2020 programme and will fund the participation in the projects of universities, small and medium-sized companies, patient groups etc. The other half comes from large pharmaceutical companies and IMI Associated Partners, who do not receive EU funding through IMI but finance their own participation in our projects.

Open access tools for the genetics of disease – Many diseases have a genetic component, yet we lack the tools to study many of the genes behind diseases. This topic aims to develop a set of open access tools to facilitate the study around 1 000 of the 3 000 genes thought to be implicated in disease and that could be targeted by drugs. The results of the project will be made fully available to the scientific community by open access.  

Optimising future obesity treatment – Obesity affects some 650 million people globally, placing them at greater risk of complications such as heart disease, diabetes and cancer to name a few. This topic aims to better understand obesity as a disease by identifying subgroups of people with obesity that will ultimately pave the way for better, more personalised prevention and lifestyle interventions, as well as treatments for obesity and its complications. The project will also focus on diabetes (both types 1 and 2) as examples of conditions that are influenced by obesity in a complex way.

Environmental impacts of medicines – Active ingredients from medicines can get into the environment through a variety of routes, and once there they can prove harmful to wildlife and ecosystems. In the EU, new medicines are required to undergo an environmental risk assessment (ERA). This topic will help to reduce the impact of medicines on the environment in three ways. Firstly, it will deliver tools to identify environmental risks associated with medicines under development. Secondly, it will prioritise which existing medicines (introduced before the ERA) should go through a tailored environmental assessment. Finally, it will create a publicly-available database to make environmental data on human medicinal products more transparent to all stakeholders.

Pierre Meulien, IMI Executive Director commented: ‘If we want to enjoy the benefits of the genomic revolution, we have to develop tools to study in detail the genes that influence our health. By taking an open access approach, the new topic launched as part of today’s Call for proposals will maximise the impacts of its results by making it possible for researchers worldwide to access and use them in their own work.

Info related to the calls is here

Webinars on all three funds here 

More info here 

NEWS​

Related News

Health Technology Procurements: Advancing Catalonia’s Digital Health Strategy

29 Apr 2025
CatSalut has published through CTTI two procurement opportunities for technology partners to support Catalonia's ambitious Digital Health Strategy 202...

Cancer Grand Challenges

29 Apr 2025
Cancer Grand Challenges is a global research initiative that identifies the toughest challenges in cancer research. With awards of up to $25m, it empo...

Global Incubator Programme: USA (Houston) Healthtech – Medical Devices

29 Apr 2025
Delivered in partnership with the Texas Medical Center Innovation (TMCi), Houston, USA and supported by the Department for Business & Trade (DBT),...

Global Business Innovation Programme: Digital Health, USA

29 Apr 2025
Innovate UK seeks up to 15 ambitious UK small businesses (with under 250 employees) who want to explore digital health opportunities in the USA.

Global Incubator Programme: Canada – AI for Health

29 Apr 2025
Delivered by Innovate UK, in partnership with MaRS, this Global Incubator Programme (GIP) provides an opportunity for UK-based companies to expand int...

Accelerated Knowledge Transfer

29 Apr 2025
Innovate UK Accelerated Knowledge Transfer (AKT) is jointly delivered by Innovate UK and Innovate UK Business Connect.

Become a member

Join ECHAlliance to amplify your organisation’s message, grow your networks, connect with innovators and collaborate globally.
 
First name *
Last Name *
Email Address *
Country *
Position *
First name *
Last Name *
Email Address *
Country *
Position *